DARA BioSciences Announces Completion of Toxicology Studies for ... - MarketWatch
DARA BioSciences Announces Completion of Toxicology Studies for ... MarketWatch - DB959 is a novel insulin sensitizer designed to correct the insulin resistance of Type 2 diabetes. In pre-clinical studies, the drug has demonstrated potent ... |